|
⚲
|
| Keyboard |
| CR Group LP
✚
|
|
|---|---|
| CRD # | 132967 |
| SEC # | 801-63545 |
| CIK # | 0001702352, 0001747755 |
| AUM | 2,207.6 M (2026-03-31) |
| Employees | 21 (43% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 713-209-7350 |
| Address | 1000 Main Street, Suite 2500 Houston, TX 77002-6340 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation CRG generally receives an annual management fee (the “Management Fee”), as described in the Client’s respective Advisory Agreements, based upon (a) during the applicable Client’s investment period, either (1) total investor commitments or (2) total invested capital or the fair value of managed assets, and (b) thereafter, total invested capital or the fair value of managed assets, as such terms are defined in the Client’s operating agreement (the “Operating Agreement”). Under the terms of each Advisory Agreement, the Management Fee is generally payable quarterly in advance, prorated for the actual number of days if less than three months; in such a case, the Adviser will return the unearned portion to the Fund. In addition, CRG may be entitled to receive carried interest or a performance fee (an “Incentive Fee”), as described in the respective Client’s Operating Agreement and Advisory Agreement. CRG may negotiate a specific fee arrangement with a particular investor pursuant to a side letter or other account agreement. CRG or its affiliates additionally may receive fees from the Funds for additional services provided to the Funds or their underlying investments not covered by the client’s management fee (“Related Services”). Any such amounts received for Related Services will generally reduce management fees paid to the Adviser. All Clients will incur expenses in connection with custodial or brokerage services discussed in Item 12. In addition, Clients bear their own operating costs and expenses relating to their organization and operations, which may include, but are not limited to expenses incurred in identifying, assessing, acquiring, negotiating, structuring, and disposing of investment opportunities, including any financing, legal, accounting, management and consulting fees whether or not a Client actually invests in the specific investment opportunity or not; administrative expenses associated with an annual audit, financial and tax returns and tax reporting to a Client’s investors; registration and other investment costs; interest and fees associated with any permitted borrowings; costs of any litigation, D&O insurance and other types of insurance, indemnification or extraordinary expense or liability; meetings of Client investors; fees and disbursements to attorneys, consultants, accountants, fund administrators, service providers and any other professionals relating to Client matters. Allocation of Expenses CRG frequently will be required to decide how certain costs and expenses are to be allocated to one or more Funds, and to other Clients of the Adviser. Certain expenses may be suitable for only a particular Fund or Funds or another participating Client and borne only by such vehicles, or, as is more often the case, expenses may be allocated pro rata among each participating Client in accordance with expense allocation policies and procedures developed by the Adviser, as may from time to time be amended or revised by the Adviser in its sole discretion. Generally, expenses are expected to be allocated based on contributions to the applicable Portfolio Investment. However, the Adviser may determine in its sole discretion that allocation in a different manner would be fair and equitable in certain cases that may result in one or more Funds bearing a higher share of expenses. For example, the Adviser may determine to use a different allocation of expense where the applicable expense has been incurred based on some factor other than asset or investment size (such as the number of investors in each parallel fund) or where the expense would be incurred by one or more parallel funds regardless of the existence of, or participation in the benefits of such expense by, another parallel fund or client. Notwithstanding the foregoing, the portion of an expense allocated to a Fund for a particular service may not reflect the relative benefit derived by the Fund from that service in any particular instance. CRG may make allocation decisions that result in a general partner or the Adviser bearing a smaller portion of expenses and/or receiving greater amounts of management fees than would have been the case had expenses been allocated pro rata. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients The Adviser provides investment management services to several Funds. Investors in the Funds may include certain qualified individuals, public pensions, corporate pension and profit- sharing plans, charitable institutions, foundations, endowments, municipalities, private investment funds, trust programs, insurance companies, sovereign funds, foreign funds and other U.S. and international institutions. CRG has also provided investment management services to separately managed accounts of investors with similar profiles as those who have invested in the Funds. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | CRG Partners V Cayman Parallel Fund C LP | [2023-03-30] | 526.5 M | 371.0 M |
| Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose | ||||
| PE | CRG Partners V Cayman Parallel Fund LP | [2023-03-30] | 526.5 M | 77.4 M |
| Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose | ||||
| PE | CRG Partners V Delaware Parallel Fund LP | [2023-03-30] | 526.5 M | 95.1 M |
| Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | CRG Partners IV - Cayman Levered LP | [2019-03-29] | 166.1 M | |
| Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | CRG Partners IV LP | [2019-03-29] | 229.8 M | 165.2 M |
| Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | CRG Partners IV - Parallel Fund C Cayman LP | [2019-03-29] | 600.0 M | 338.3 M |
| Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | CRG Partners III Cayman LP | [2016-03-29] | 89.0 M | 61.9 M |
| Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $399,000 · Revenue Decline to Disclose | ||||
| PE | CRG Partners III LP | [2016-03-29] | 41.5 M | 26.5 M |
| Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $124,500 · Revenue Decline to Disclose | ||||
| PE | CRG Partners III - Parallel Fund A LP | [2016-03-29] | 27.3 M | 18.9 M |
| Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $409,500 · Revenue Decline to Disclose | ||||
| PE | CRG Partners III - Parallel Fund B Cayman LP | 2016-03-29 | 55.0 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 2.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 2.2 |
| By Discretionary | ||
| Discretionary | 10 | 2.2 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 2.2 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.7 | |
| United States Persons | 0.5 | |
| Total | 10 | 2.2 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Sabrina Foster | Director | 43 | 16 | |
| Omar Wright | Director | 88 | 13 | |
| Charles Tate | Executive Officer | 16 | 2 | |
| Nathan Hukill | Executive Officer, Promoter | 9 | 2 | |
| Andrei Dorenbaum | Executive Officer, Promoter | 7 | 2 | |
| Luke Duster | Executive Officer, Promoter | 6 | 2 | |
| Sebastian Arango | Promoter | 3 | 1 | |
| Adam Whitehead | Promoter | 3 | 1 | |
| Meredith Gamble | Promoter | 3 | 1 | |
| Crg Partners V Cayman GP LP | Executive Officer | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001702352] | |
| 4 | [0001702352] | |
| SC 13D | [0001702352] | |
| SC 13G | [0001702352] | |
| D | [0001747755] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.0B |
| Serves | Institutional |
| Fund Types | Private Equity |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-09 | Conversion | 108,752 | ||
|
T2 Biosystems Inc TTOO
Series A Preferred Stock · derivative
|
2024-05-09 | Conversion | 17,160.48 | $0.00 | |
|
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
|
2024-05-09 | Conversion | 10,875.25 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-09 | Conversion | 1,716,048 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 403,608 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 1,565,445 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 129,629 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 648,139 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-05-03 | Grant | 2,001,514 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 424,716 | ||
|
T2 Biosystems Inc TTOO
Series A Convertible Preferred Stock · derivative
|
2024-04-12 | Grant | 17,160.48 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 1,647,315 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 682,036 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 390,142 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-04-12 | Grant | 136,409 | ||
|
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
|
2024-02-14 | Conversion | 33,594.71 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-02-14 | Conversion | 335,947 | ||
|
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
|
2024-02-14 | Conversion | 48,827.30 | $0.00 | |
|
T2 Biosystems Inc TTOO
Common Stock
|
2024-02-14 | Conversion | 488,273 | ||
|
T2 Biosystems Inc TTOO
Common Stock
|
2023-09-28 | Sell | 2,858,980 | $0.16 | 457,437 |
| showing 20 of 98 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Hidden Harbor Capital Management LP
✚
|
FL | 2,235.2 M |
|
EIV Capital LLC
✚
|
TX | 2,232.2 M |
|
CCMP Capital Advisors LP
✚
|
NY | 2,229.0 M |
|
Two Sigma Ventures LP
✚
|
NY | 2,226.1 M |
|
Longrange Capital LP
✚
|
CT | 2,219.6 M |
|
Further Global Capital Management LP
✚
|
NY | 2,215.6 M |
|
Kosmos Management LLC
✚
|
WA | 2,205.9 M |
|
Pacific Lake Partners LLC
✚
|
MA | 2,179.9 M |
|
CAI Manager LP
✚
|
CA | 2,177.7 M |
|
Ascend Capital Partners Manager LP
✚
|
NY | 2,176.3 M |